---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000060"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:42:15.572287+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa Q4 net loss $43.2M; cash $393.6M; SerpinPC, LB101, ORX750 progress

## Summary
- Cash and cash equivalents $393.6M as of Dec 31, 2022; expected to fund operations into 2026.
- Net loss attributable to ordinary shareholders $43.2M for Q4 2022 vs $60.8M in Q4 2021.
- SerpinPC registrational program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected in 2023.
- First subject dosed in Phase 1/2a trial of LB101 (PD-L1xCD47 LockBody) for solid tumors.
- ORX750 nominated as product candidate for narcolepsy; preclinical data expected at scientific meeting in 2023.

## SEC filing metadata
- accession: 0001847903-23-000060
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/0001847903-23-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/cnta-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000060
- JSON: https://secwatch.observer/filing/0001847903-23-000060.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000060.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2022.
  - Period: the fourth quarter and full-year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/0001847903-23-000060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.